Fmr Llc ownership in 10V / Immunic, Inc.

Immunic, Inc.

DE ˙ DB

16,63 EUR ↓ -16,55 (-49,87%)

2019-04-18
PREȚUL ACȚIUNILOR

Security	DE:10V / Immunic, Inc.
Institution	Fmr Llc
Latest Disclosed Ownership	509,372 shares
Ownership	1.94%

2022-02-09 - Fmr Llc has filed an SC 13G/A form with the Securities and Exchange Commission (SEC) disclosing ownership of 509,372 shares of Immunic, Inc. (DE:10V). This represents 1.94 percent ownership of the company. In their previous filing dated 2021-02-08 , Fmr Llc had reported owning 1,320,542 shares, indicating a decrease of -61.43 percent.

Institutional Ownership: 13D/G Filings

This table shows a history of the 13D/G filings made by the investor and/or investor group. Note that the share values in this table are not directly comparable to any numbers shown in the 13F table (if any).

File Date	Effective Date	Form	Prev Shares	Latest Shares	ΔShares (Percent)	Ownership (Percent)	ΔOwnership (Percent)
2022-02-09	2022-02-09	13G/A	1,320,542	509,372	-61.43	1.94	-69.56
2021-02-08	2021-02-08	13G	1,457,878	1,320,542	-9.42	6.37	40.13
2017-02-14	2017-02-14	13G/A	1,575,469	1,457,878	-7.46	4.55	-9.80
2016-08-10	2016-08-10	13G/A	3,289,660	1,575,469	-52.11	5.04	-53.58
2015-11-10	2015-11-10	13G/A		3,289,660		10.86
2015-02-13	2015-02-13	13G		1,750,000		7.34

Important Note: One of the primary uses of the 13D/G filings is to evaluate the ability of a firm to control a company (ie, the "beneficial ownership"). To that end, firms are required to report not just direct holdings in companies, but indirect holdings that they control. For investment firms, these indirect holdings can include shares in funds they manage, advisory accounts, and in the case of activist campaigns, pledged votes. Therefore, share counts listed in 13D/G filings can differ significantly than share counts listed in 13F filings.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel Premium Registration Required .

Disclosed Equity Positions (from 13F/NPORT Filings)

File Date	Effective Date	Form	Security	Class	ID	Reported Shares	ΔShares	ΔShares (%)	Reported Value (x1000)	ΔValue (%)	Alloc (%)
2026-05-15	2026-03-31	13F	IMMUNIC	COM	4525EP101	455	455		1		0.0000
2025-05-12	2025-03-31	13F	IMMUNIC	COM	4525EP101	0	-1	-100.00	0		0.0000
2025-02-13	2024-12-31	13F	IMMUNIC	COM	4525EP101	1	1		0		0.0000
2024-02-13	2023-12-31	13F	IMMUNIC	COM	4525EP101	0	-3,577	-100.00	0	-100.00
2023-11-13	2023-09-30	13F	IMMUNIC	COM	4525EP101	3,577	-12,834	-78.20	5	-87.80	0.0000
2023-08-11	2023-06-30	13F	IMMUNIC	COM	4525EP101	16,411	3,413	26.26	41	115.79	0.0000
2023-08-11	2023-03-31	13F/A-1	IMMUNIC	COM	4525EP101	12,998	-1,366	-9.51	19	-5.00	0.0000
2023-05-11	2023-03-31	13F	IMMUNIC	COM	4525EP101	12,998	-1,366		19		0.0000
2023-02-13	2022-12-31	13F	IMMUNIC	COM	4525EP101	14,364	-495,016	-97.18	20	-98.76	0.0000
2022-11-10	2022-09-30	13F	IMMUNIC	COM	4525EP101	509,380	-172	-0.03	1,610	-8.94	0.0002
2022-08-12	2022-06-30	13F	IMMUNIC	COM	4525EP101	509,552	-596	-0.12	1,768	-69.33	0.0002
2022-05-13	2022-03-31	13F	IMMUNIC	COM	4525EP101	510,148	776	0.15	5,765	18.26	0.0005
2022-02-14	2021-12-31	13F	IMMUNIC	COM	4525EP101	509,372	-555,917	-52.18	4,875	-48.29	0.0004
2022-02-14	2021-09-30	13F/A-1	IMMUNIC	COM	4525EP101	1,065,289	-127,433	-10.68	9,427	-35.53	0.0007
2021-11-15	2021-09-30	13F	IMMUNIC	COM	4525EP101	1,065,289	-127,433		9,427		0.0007
2021-08-13	2021-06-30	13F	IMMUNIC	COM	4525EP101	1,192,722	7,380	0.62	14,623	-22.61	0.0011
2021-05-14	2021-03-31	13F	IMMUNIC	COM	4525EP101	1,185,342	-135,200	-10.24	18,895	-6.42	0.0016
2021-02-08	2020-12-31	13F	IMMUNIC	COM	4525EP101	1,320,542	324,072	32.52	20,192	9.12	0.0018
2020-11-13	2020-09-30	13F	IMMUNIC	COM	4525EP101	996,470	859,279	626.34	18,504	1,012.69	0.0019
2020-08-24	2020-06-30	13F/A-1	IMMUNIC	COM	4525EP101	137,191	137,191		1,663		0.0002
2020-08-13	2020-06-30	13F	IMMUNIC	COM	4525EP101	137,191	137,191		1,663		40.8550
2018-11-09	2018-09-30	13F	VITAL THERAPIES	COM	92847R104	0	-764,378	-100.00	0	-100.00
2018-08-10	2018-06-30	13F	VITAL THERAPIES	COM	92847R104	764,378	-1,160,165	-60.28	5,236	-59.99	0.0006
2018-05-14	2018-03-31	13F	VITAL THERAPIES	COM	92847R104	1,924,543	-36,935	-1.88	13,087	12.13	0.0016
2018-02-12	2017-12-31	13F	VITAL THERAPIES	COM	92847R104	1,961,478	-996,400	-33.69	11,671	-21.87	0.0014
2017-11-13	2017-09-30	13F	VITAL THERAPIES	COM	92847R104	2,957,878	0	0.00	14,937	74.13	0.0018
2017-08-29	2017-06-30	13F/A-1	VITAL THERAPIES	COM	92847R104	2,957,878	0	0.00	8,578	-27.50	0.0011
2017-08-11	2017-06-30	13F	VITAL THERAPIES	COM	92847R104	2,957,878	0		8,578
2017-05-11	2017-03-31	13F	VITAL THERAPIES	COM	92847R104	2,957,878	1,500,000	102.89	11,832	86.57	0.0015
2017-02-10	2016-12-31	13F	VITAL THERAPIES	COM	92847R104	1,457,878	0	0.00	6,342	-28.92	0.0008
2016-11-14	2016-09-30	13F	VITAL THERAPIES	COM	92847R104	1,457,878	-559,482	-27.73	8,922	-28.67	0.0012
2016-08-11	2016-06-30	13F	VITAL THERAPIES	COM	92847R104	2,017,360	-731,443	-26.61	12,508	-49.83	0.0017
2016-05-16	2016-03-31	13F	VITAL THERAPIES	COM	92847R104	2,748,803	-540,857	-16.44	24,932	-34.21	0.0034
2016-02-12	2015-12-31	13F	VITAL THERAPIES	COM	92847R104	3,289,660	1,818,181	123.56	37,897	537.46	0.0051
2015-11-10	2015-09-30	13F	VITAL THERAPIES	COM	92847R104	1,471,479	-320,000	-17.86	5,945	-84.27	0.0008
2015-08-25	2015-06-30	13F/A-1	VITAL THERAPIES	COM	92847R104	1,791,479	-278,521	-13.46	37,800	-26.99	0.0048
2015-08-13	2015-06-30	13F	VITAL THERAPIES	COM	92847R104	1,791,479			37,800
2015-05-14	2015-03-31	13F	VITAL THERAPIES	COM	92847R104	2,070,000	320,000	18.29	51,771	18.66	0.0066
2015-02-17	2014-12-31	13F	VITAL THERAPIES	COM	92847R104	1,750,000	500,000	40.00	43,628	71.00	0.0057
2014-11-14	2014-09-30	13F	VITAL THERAPIES	COM	92847R104	1,250,000	0	0.00	25,513	-25.07	0.0035
2014-08-14	2014-06-30	13F	VITAL THERAPIES	COM	92847R104	1,250,000	1,250,000		34,050		0.0046

Legend

Shares: The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value: The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price: The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class: This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred

Allocation (%): The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation: The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%): The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis: The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss: This is the market value of the position as of the effective date minus the cost basis.